Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine + Cytarabine for MRD+ Leukemia
NCT01158885Phase 2Terminated
- Sponsor
- Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium
- Start
- Aug 2010
- Primary completion
- Oct 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium. Primary endpoint: Minimal Residual Disease. Started Aug 2010; status: terminated.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01158885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01158885.